BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25280532)

  • 1. Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
    Novitskiy SV; Forrester E; Pickup MW; Gorska AE; Chytil A; Aakre M; Polosukhina D; Owens P; Yusupova DR; Zhao Z; Ye F; Shyr Y; Moses HL
    Breast Cancer Res; 2014 Oct; 16(5):425. PubMed ID: 25280532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
    Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
    Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.
    Vasiukov G; Novitskaya T; Zijlstra A; Owens P; Ye F; Zhao Z; Moses HL; Blackwell T; Feoktistov I; Novitskiy SV
    Cancer Res; 2020 Jun; 80(12):2628-2638. PubMed ID: 32312837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenascin-C increases lung metastasis by impacting blood vessel invasions.
    Sun Z; Velázquez-Quesada I; Murdamoothoo D; Ahowesso C; Yilmaz A; Spenlé C; Averous G; Erne W; Oberndorfer F; Oszwald A; Kain R; Bourdon C; Mangin P; Deligne C; Midwood K; Abou-Faycal C; Lefebvre O; Klein A; van der Heyden M; Chenard MP; Christofori G; Mathelin C; Loustau T; Hussenet T; Orend G
    Matrix Biol; 2019 Oct; 83():26-47. PubMed ID: 31288084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic acceleration of Neu induced mammary tumor progression and metastasis.
    Oshima RG; Lesperance J; Munoz V; Hebbard L; Ranscht B; Sharan N; Muller WJ; Hauser CA; Cardiff RD
    Cancer Res; 2004 Jan; 64(1):169-79. PubMed ID: 14729621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
    Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL
    Am J Pathol; 2003 Oct; 163(4):1539-49. PubMed ID: 14507660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CdGAP is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion.
    He Y; Northey JJ; Primeau M; Machado RD; Trembath R; Siegel PM; Lamarche-Vane N
    Oncogene; 2011 Mar; 30(9):1032-45. PubMed ID: 21042277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.
    Pickup MW; Laklai H; Acerbi I; Owens P; Gorska AE; Chytil A; Aakre M; Weaver VM; Moses HL
    Cancer Res; 2013 Sep; 73(17):5336-46. PubMed ID: 23856251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.
    Wong AW; Dunlap SM; Holcomb VB; Nunez NP
    Alcohol Clin Exp Res; 2012 Apr; 36(4):577-87. PubMed ID: 21981381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL
    Cancer Res; 2008 Mar; 68(6):1809-19. PubMed ID: 18339861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer.
    Huang F; Shi Q; Li Y; Xu L; Xu C; Chen F; Wang H; Liao H; Chang Z; Liu F; Zhang XH; Feng XH; Han JJ; Luo S; Chen YG
    Cancer Res; 2018 Nov; 78(21):6073-6085. PubMed ID: 30171053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of CXCL12 secretion to invasion of breast cancer cells.
    Boimel PJ; Smirnova T; Zhou ZN; Wyckoff J; Park H; Coniglio SJ; Qian BZ; Stanley ER; Cox D; Pollard JW; Muller WJ; Condeelis J; Segall JE
    Breast Cancer Res; 2012 Feb; 14(1):R23. PubMed ID: 22314082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
    Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
    Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.
    Shaw AK; Pickup MW; Chytil A; Aakre M; Owens P; Moses HL; Novitskiy SV
    PLoS One; 2015; 10(1):e0117908. PubMed ID: 25629162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
    Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
    J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.
    Chow A; Arteaga CL; Wang SE
    J Mammary Gland Biol Neoplasia; 2011 Jun; 16(2):81-8. PubMed ID: 21590373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.